Month: February 2022

Fast Track designation granted by the U.S. Food and Drug Administration (FDA) to Wee1 Inhibitor, ZN-c3, for the treatment of uterine serous carcinoma (USC) Initiated two additional trials with ZN-c3, including a potentially registrational biomarker-driven Phase 2 trial and a Phase 1/2 trial in combination with GSK’s PARP inhibitor, niraparib, in ovarian cancer Announced the addition of a preclinical BCL-xL heterobifunctional degrader candidate to its pipeline Ended year with $339.9 million in cash, cash equivalents and short-term investments NEW YORK and SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) — Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced financial...

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) — Acreage Holdings, Inc. (“Acreage”) (CSE:ACRG.A.U, ACRG.B.U), (OTCQX: ACRHF, ACRDF), a vertically integrated, multi-state operator of cannabis cultivation and retailing facilities in the U.S., today announced it will report its fourth quarter and full year 2021 financial results for the period ending December 31, 2021, on March 10, 2022, after market close. Management will host a conference call on March 11, 2022, at 10:00 a.m. ET to discuss the results in detail. Conference call details:Date: Friday, March 11, 2022Time: 10:00 a.m. ETWebcast: Click hereDial-in: Canada – (833) 950-0062 (toll-free) or (226) 828-7575 (local)  US – (844) 200-6205 (toll-free) or (646) 904-5544 (local)Conference ID: 129591The webcast will be archived and can be accessed via Acreage’s...

– Received FDA Approval of PYRUKYND® (mitapivat) for the Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase (PK) Deficiency; First Approved Therapy for this Rare Blood Disorder – – First Patients Dosed in All Three Pivotal Trials of PYRUKYND® in Thalassemia and Sickle Cell Disease – – Cash, Cash Equivalents and Marketable Securities $1.3 Billion as of Dec. 31; Expects Strong Cash Position to Enable Execution of Robust Operating Plan to Cash-Flow Positivity – CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today reported business highlights and financial results for the fourth quarter and year ended Dec. 31, 2021. “With last week’s FDA approval of PYRUKYND® for the treatment...

NEW HAVEN, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its fourth quarter and full year 2021 financial results on Thursday, March 10, 2022 before the open of the U.S. financial markets. BioXcel Therapeutics’ management team will also host a conference call and webcast at 8:30 AM ET to discuss the Company’s financial results and to provide a general business update.Conference Call & Webcast Details   Date/Time: Thursday, March 10, 2022 at 8:30 AM Eastern TimeDomestic: 877-407-5795International: 201-689-8722The webcast and the accompanying materials will be accessible* under...

EMERYVILLE, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer will participate in the “Infectious Disease” panel at the Cowen 42nd Annual Health Care Conference, which is being held virtually from March 7 to 9. Panel DetailsTitle: Infectious DiseaseDate and Time: Wednesday, March 9th from 10:30 – 11:30 a.m. ET A live webcast of the panel will be accessible via the Investors & Media section of the company’s website at https://ir.gritstonebio.com/investors/events. An archived replay will be accessible for 30 days following the event. About Gritstone bioGritstone bio, Inc. (Nasdaq: GRTS),...

PHILADELPHIA, Feb. 24, 2022 (GLOBE NEWSWIRE) — Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 3, 2022 to report its fourth quarter and full-year 2021 financial results and discuss recent business highlights. To access the live conference call, please dial 833-528-0605 (domestic) or 830-221-9711 (international) and refer to conference ID 4137048. A live audio webcast of the event will be available on the Investors & News section of Passage Bio’s website at investors.passagebio.com. The archived webcast will be available on Passage Bio’s website approximately two hours after the completion of the event and...

FRANKLIN, Ind., Feb. 24, 2022 (GLOBE NEWSWIRE) — IBC Advanced Alloys Corp. (TSX-V: IB; OTCQB: IAALF) (“IBC” or the “Company”) a leading beryllium and copper advanced alloys company, announced today that it will host a live webcast and conference call for investors and the general public on Wednesday, March 2, 2022, starting at 12 Noon Eastern. The webcast and conference call will feature Mark A. Smith, IBC CEO and Board Chairman, who will discuss the Company’s financial results for the quarter ended December 31, 2022, which are expected to be released on March 1, 2022, after market close. To register for the webinar and conference call, and receive instructions on how to call in or connect via the internet to the webinar, please go here: https://attendee.gotowebinar.com/register/138217828988545037 A recording of the webcast...

GREENWICH, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) — XPO Logistics, Inc. (NYSE: XPO), a leading provider of freight transportation services, has been awarded Carrier Partner of the Year for its less-than-truckload (LTL) performance by GlobalTranz Enterprises, LLC. This is the second year that XPO’s North American LTL business has been honored by GlobalTranz, a technology-driven, third-party logistics provider with extensive industry relationships. GlobalTranz determined its 2021 Carriers of the Year based on six criteria: financial performance, growth, customer service, collaboration, technological innovation and overall excellence. Mario Harik, acting president, less-than-truckload, and chief information officer of XPO Logistics, said, “Our partnership with GlobalTranz is based on delivering value for LTL shippers through technological...

CMX521 Significantly Reduced Lung Viral Titer and Clinical Symptoms in a SARS-CoV-2 Mouse Model DURHAM, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), in collaboration with the Rapidly Emerging Antiviral Drug Development Initiative at the University of North Carolina at Chapel Hill, today announced that preclinical data from the Company’s CMX521 program will be featured in a late-breaking oral presentation session at the International Conference on Antiviral Research (ICAR) on Wednesday, March 23, 2022 from 12:15 – 1:00 pm PT. “While we focus on the advancement of our oncology pipeline and progress toward a TEMBEXA procurement agreement with BARDA, this collaboration with READDI allows us to efficiently evaluate our antiviral library to identify molecules that might have value to patients,” said Mike Sherman, Chief...

— Analysis from APeX-2 showed 94 percent attack-free days across all patients who completed 96 weeks of treatment — RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new long-term efficacy and safety data from the APeX-2 clinical trial evaluating oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) showing sustained reductions in attack rates and improvement in quality of life (QoL) among patients living with HAE, regardless of their baseline attack rates and initial responses to ORLADEYO. The data are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, which is being held live in Phoenix, Arizona, and virtually, from February 25-28, 2022. “The long-term...